FDA — authorised 27 December 1971
- Application: NDA013993
- Marketing authorisation holder: BRACCO
- Local brand name: CHROMITOPE SODIUM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA authorised SODIUM CHROMATE CR 51 on 27 December 1971
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 27 December 1971; FDA has authorised it.
BRACCO holds the US marketing authorisation.